Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

779.67 -2.71 (-0.35%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

49 50 Next >

The 7 Best Biotech Stocks to Buy for February 2023 ↗

February 07, 2023

Following the wave of red ink last year, astute investors should target the best biotech stocks to buy this month for strong growth potential.

Via InvestorPlace

Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review ↗

February 03, 2023

The major indexes continued to run despite mixed-to-weak earnings.

Via Investor's Business Daily

Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples ↗

February 03, 2023

Regeneron beat forecasts despite wide declines. But Sanofi fell on its mixed report.

Via Investor's Business Daily

Regeneron Pharmaceuticals Q4 Earnings: Revenue Falls As COVID-19-Related Sales Dwindle ↗

February 03, 2023

Via Benzinga

Regeneron Pharmaceuticals's Earnings Outlook ↗

February 02, 2023

Via Benzinga

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today ↗

February 01, 2023

Via Benzinga

What 8 Analyst Ratings Have To Say About Regeneron Pharmaceuticals ↗

January 30, 2023

Via Benzinga

Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact ↗

February 03, 2023

Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each...

Via Benzinga

The 7 Most Undervalued Stocks to Buy in February 2023 ↗

February 02, 2023

These undervalued stocks to buy are under-appreciated, and have substantial upside as we move deeper into the new year.

Via InvestorPlace

The 7 Most Undervalued Biotech Stocks to Buy in February 2023 ↗

February 02, 2023

Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy.

Via InvestorPlace

The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023 ↗

February 01, 2023

For those seeking the best discounts in the tech-centered index, these are the most undervalued Nasdaq stocks to buy.

Via InvestorPlace

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years ↗

January 19, 2023

Via Benzinga

Analyst Ratings for Regeneron Pharmaceuticals ↗

January 11, 2023

Via Benzinga

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

7 CRISPR Stocks With the Best Long-Term Potential ↗

January 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Via InvestorPlace

Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis ↗

January 30, 2023

Via Benzinga

Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023 ↗

January 23, 2023

It's difficult to imagine a future where healthcare isn't in high demand.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023 ↗

January 30, 2023

Via Benzinga

J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps ↗

January 17, 2023

Large cap biopharmas that outperformed in 2022 were generally weak last week from profit-taking and portfolio rebalancing.

Via Talk Markets

Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review ↗

January 13, 2023

Sharp Tesla price cuts and some notable earnings were in focus.

Via Investor's Business Daily

Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch ↗

January 29, 2023

With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.

Via Benzinga

Check Out What Whales Are Doing With REGN ↗

January 10, 2023

A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 15 strange...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 20, 2023 ↗

January 20, 2023

Via Benzinga

Check Out What Whales Are Doing With REGN ↗

January 09, 2023

Via Benzinga

Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin ↗

January 09, 2023

Regeneron Pharmaceuticals says sales of linchpin Eylea drug have been negatively impacted rival drug Avastin. REGN stock plunged on the news.

Via Investor's Business Daily

What This Drug News Could Mean for Sanofi Shareholders ↗

January 08, 2023

This star drug for Sanofi is one step closer to approval in the European Union for another chronic inflammatory disease.

Via The Motley Fool

5 Top Pharma Stocks of 2022 to Buy for the Long Haul ↗

January 06, 2023

The biggest drug company blockbusters bring in billions of dollars, which is one of the reasons to consider these top Pharma stocks.

Via InvestorPlace

CytomX Shares Move Higher On Collaborating Pact With This Famed COVID-19 Vaccine Maker ↗

January 06, 2023

Via Benzinga

3 Growth Stocks That Could Rocket Higher in 2023 ↗

January 06, 2023

Upcoming binary events could push these stocks to new all-time highs.

Via The Motley Fool

Jim Cramer Says He's 'Still Feeling Good' About These 5 Stocks From 'Mutilated' Nasdaq ↗

January 05, 2023

Prominent market commentator Jim Cramer has recommended five stocks from the Nasdaq Index that he believes could be decent additions to investors’ portfolios.

Via Benzinga

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

49 50 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Regeneron Pharmaceuticals (NQ:REGN)

Headline News about Regeneron Pharmaceuticals

Starting at $3.75/week.

Subscribe Today